Aktuellt
SENASTE
Redeye is encouraged by the recent announcement from Egetis Therapeutics that it has secured a total of SEK462m through a combined private placement/directed issue of SEK172m, slightly above the previous day's closing rate, and a debt financing of SEK290m. This funding should provide the company with sufficient resources to advance Emcitate past approval and reduce the financial risk significantly. We will provide a more detailed comment shortly.
LÄS MER
